A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

Inclusion Criteria: \- Have clinically stable symptomatic heart failure (HF) (heart failure with reduced ejection fraction \[HFrEF\] and heart failure with preserved ejection fraction \[HFpEF\]): (A) For HFrEF: (a) ejection fraction (EF) less than or equal to (\<=) 40 percent (%) and (b) a primary diagnosis of HF OR 2 medical visits (including virtual) with a HF diagnosis code in any position in the past 18 months (B) For HFpEF: (a) EF greater than (\>) 40%; (b) a primary diagnosis of HF OR 2 medical visits (including virtual) with a HF diagnosis code in any position in the past 18 months, AND; (C) on a loop diuretic or spironolactone or eplerenone (mineralocorticoid receptor antagonists), in the past 18 months * Have a baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) score of less than or equal to (\<=) 80 prior to randomization * Be able to read and understand English * Possess and have sole use (example: not shared with other users) of smartphone compatible with the Fitbit device * Willing/able to wear the Fitbit device on a regular basis for the 9-month study period Exclusion Criteria: * Currently taking a sodium-glucose co-transporter 2 inhibitor (SGLT2i) or within the last 3 months * History of diabetic ketoacidosis or have type 1 diabetes mellitus (T1DM) * Have acute decompensated HF (exacerbation of symptomatic HF) requiring intravenous diuretics, inotropes, or vasodilators within the last 4 weeks * Have stage 4 or 5 Chronic Kidney Disease (that is, estima…